+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Prognostic Model Based on Systemic Inflammatory Response and Clinicopathological Factors to Predict Outcome of Patients with Node-Negative Gastric Cancer



Prognostic Model Based on Systemic Inflammatory Response and Clinicopathological Factors to Predict Outcome of Patients with Node-Negative Gastric Cancer



Plos One 10(6): E0128540



Prognostic models are generally used to predict gastric cancer outcomes. However, no model combining patient-, tumor- and host-related factors has been established to predict outcomes after radical gastrectomy, especially outcomes of patients without nodal involvement. The aim of this study was to develop a prognostic model based on the systemic inflammatory response and clinicopathological factors of resectable gastric cancer and determine whether the model can improve prognostic accuracy in node-negative patients. We reviewed the clinical, laboratory, histopathological and survival data of 1397 patients who underwent radical gastrectomy between 2007 and 2013. Patients were split into development and validation sets of 1123 and 274 patients, respectively. Among all 1397 patients, 545 had node-negative gastric cancer; 440 were included in the development set, 105 were included in the validation set. A prognostic model was constructed from the development set. The scoring system was based on hazard ratios in a Cox proportional hazard model. In the multivariate analysis, age, tumor size, Lauren type, depth of invasion, lymph node metastasis, and the neutrophil--lymphocyte ratio were independent prognostic indicators of overall survival. A prognostic model was then established based on the significant factors. Patients were categorized into five groups according to their scores. The 3-year survival rates for the low- to high-risk groups were 98.9%, 92.8%, 82.4%, 58.4%, and 36.9%, respectively (P < 0.001). The prognostic model clearly discriminated patients with stage pT1-4N0M0 tumor into four risk groups with significant differences in the 3-year survival rates (P < 0.001). Compared with the pathological T stage, the model improved the predictive accuracy of the 3-year survival rate by 5% for node-negative patients. The prognostic scores also stratified the patients with stage pT4aN0M0 tumor into significantly different risk groups (P = 0.004). Furthermore, the predictive value of this model was validated in an independent set of 274 patients. This model, which included the systemic inflammatory markers and clinicopathological factors, is more effective in predicting the prognosis of node-negative gastric cancer than traditional staging systems. Patients in the high-risk group might be good candidates for adjuvant chemotherapy.

(PDF emailed within 0-6 h: $19.90)

Accession: 058635097

Download citation: RISBibTeXText

PMID: 26075713

DOI: 10.1371/journal.pone.0128540


Related references

Systemic prognostic score and nomogram based on inflammatory, nutritional and tumor markers predict cancer-specific survival in stage II-III gastric cancer patients with adjuvant chemotherapy. Clinical Nutrition 2018, 2018

Prognostic value of scores based on malnutrition or systemic inflammatory response in patients with metastatic or recurrent gastric cancer. Nutrition and Cancer 66(8): 1362-1370, 2015

Expression of Bcl-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to one course of perioperative chemotherapy. British Journal of Cancer 74(1): 78-85, 1996

A prognostic model based on lymph node metastatic ratio for predicting survival outcome in gastric cancer patients with N3b subclassification. Asian Journal of Surgery 2017, 2017

Prognostic factors for patients with node-negative gastric cancer: Can extended lymph node dissection have a survival benefit?. Journal of Surgical Oncology 94(1): 16-20, 2006

Prognostic factors in 138 patients with node-negative gastric cancer. Zhonghua Wei Chang Wai Ke Za Zhi 14(3): 192-195, 2013

Significant prognostic factors in patients with node-negative gastric cancer. International Surgery 84(4): 331-336, 2000

Prognostic factors in patients with node-negative gastric cancer: an Indian experience. World Journal of Surgical Oncology 9: 48, 2011

Analysis of prognostic factors in lymph node-negative advanced gastric cancer patients. Zhonghua Wei Chang Wai Ke Za Zhi 14(2): 111-113, 2012

A multicentric Western analysis of prognostic factors in advanced, node-negative gastric cancer patients. Annals of Surgery 252(1): 70-73, 2010

Prognostic Factors for Survival in Node-Negative Gastric Cancer Patients Who Underwent Curative Resection. Scandinavian Journal of Surgery 106(3): 235-240, 2017

Prognostic factors in patients with node-negative gastric cancer: a single center experience from China. Journal of Gastrointestinal Surgery 16(6): 1123-1127, 2012

A prognostic model to predict clinical outcome in gastric cancer patients with bone metastasis. Oncology 80(1-2): 142-150, 2011

Prognostic factors on overall survival in lymph node negative gastric cancer patients who underwent curative resection. Journal of Gastric Cancer 12(4): 210-216, 2013

The influence of classical prognostic factors and adjuvant chemotherapy on disease outcome in early grade 3 node-negative, and 13 node-positive breast cancer patients treated with adjuvant cyclophosphamide, methotrexate and fluorouracil (CMF), or untreated patients. European Journal of Cancer Supplements 2(3): 76-77, 2004